MedPath

The effect of Rosiglitazone on negative symptoms in schizophrenia

Phase 2
Conditions
Schizophrenia.
Schizophrenia
Registration Number
IRCT20090117001556N159
Lead Sponsor
niversity of social welfare and rehabilitation sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
50
Inclusion Criteria

Diagnosis of schizophrenia based on DSM-5
Age between 18-50
At least 2 years have been passed since the diagnosis
Have been stable with risperidone treatment for at least 2 months
Normal ECG

Exclusion Criteria

Head trauma
History of shock therapy during the last three months
Neurosurgery
Diagnosis of acute or chronic systemic disease
Alcohol or drug addiction in the last 6 months
Suicidal ideation
Pregnancy or lactation
IQ less than 70 based on the diagnosis of a psychiatrist
ECT during recent two months
Taking oral antipsychotics, excluding risperidone, in the past week or long-acting antipsychotics in the past month
The presence of another diagnosis in axis II
History of heart disease
Family history of heart disease and heart failure
Taking insulin
Liver disorders
The development of a drug complication that requires emergency action: edema, congestive heart failure, heart pain and changes in the basic ECG, hypoglycemia, the occurrence of malignant neuroleptic syndrome

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath